Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
21 studies found for:    Open Studies | "Inflammatory Breast Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Inflammatory Breast Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Case-Control Study of Inflammatory Breast Cancer in North Africa
Condition: Inflammatory Breast Cancer
Intervention:
2 Recruiting Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: Docetaxel;   Biological: Trastuzumab
3 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
4 Recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
5 Recruiting A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Conditions: Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
6 Not yet recruiting Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Conditions: HER2/Neu Negative;   Recurrent Inflammatory Breast Carcinoma;   Stage IV Breast Cancer;   Stage IV Inflammatory Breast Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
7 Not yet recruiting A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy
Conditions: Inflammatory Breast Cancer;   Malignant Neoplasm of Breast
Intervention: Drug: Pembrolizumab
8 Recruiting Inflammatory Breast Cancer (IBC) Registry
Condition: Breast Cancer
Interventions: Other: Interview;   Procedure: Blood and Tissue Collection
9 Recruiting MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer
Condition: Breast Cancer
Intervention:
10 Recruiting Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: BIBF 1120;   Behavioral: Phone Call
11 Recruiting MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: MK-3475;   Behavioral: Follow Up/Phone Call
12 Recruiting A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
Condition: Malignant Neoplasm of Breast
Interventions: Procedure: Breast Core Biopsy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Panitumumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mammogram;   Procedure: Ultrasound;   Other: Follow Up
13 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib
14 Recruiting Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence
Condition: Breast Cancer
Interventions: Drug: Talimogene Laherparepvec (T-VEC);   Other: Photographs;   Behavioral: Follow-Up Visit/Phone Call
15 Recruiting Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy
Conditions: Invasive Ductal Breast Cancer;   Tubular Breast Cancer;   Mucinous Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: 5-fluoruracil
16 Recruiting Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Conditions: Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Gonadotropin-releasing hormone agonist;   Drug: Letrozole
17 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage IIA Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer;   Stage IIB Breast Cancer;   Estrogen Receptor Negative;   Progesterone Receptor Negative;   HER2/Neu Negative
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
18 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab
19 Recruiting A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Conditions: Tubular Breast Cancer Stage II;   Tubular Breast Cancer Stage III;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: non-pegylated liposomal doxorubicin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Ferric carboxymaltose
20 Recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Breast Adenocarcinoma;   Inflammatory Breast Carcinoma
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.